for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-FDA Approves Clovis Oncology's Rubraca For Certain Prostate Cancer Patients

May 15 (Reuters) - Clovis Oncology Inc:

* RUBRACA® (RUCAPARIB) APPROVED IN THE U.S. AS MONOTHERAPY TREATMENT FOR PATIENTS WITH BRCA1/2-MUTANT, METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY

* CLOVIS ONCOLOGY INC - ACCELERATED APPROVAL BASED ON OBJECTIVE RESPONSE RATE (ORR) AND DURATION OF RESPONSE (DOR) DATA FROM TRITON2 CLINICAL TRIAL(I) Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up